FDA approves Viagra ingredient for pulmonary hypertension

Share this article:
The FDA has approved sildenafil citrate, the active ingredient in Viagra, to treat pulmonary hypertension, Pfizer said yesterday.
The compound will be called Revatio and will be sold in a 20 mg pill that is white and round to distinguish it from Viagra's blue diamond-shaped pill for erectile dysfunction sold in 25,50 or 100 mg dosages. Pfizer expects Revatio to be available in retail pharmacies in mid-July.
Pulmonary arterial hypertension is a rare, aggressive and life-shortening vascular disease characterized by dangerously high pressure in the blood vessels that lead from the heart to the lungs.  It is estimated to affect approximately 100,000 people worldwide.
The new application may add several hundred million dollars to Viagra sales, which were $1.68 billion last year, SunTrust Robinson Humphrey analyst Bert Hazlett told Bloomberg News.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.